Related Experiment Videos
Thrombolytic therapy: future issues
1Service d'Hématologie Biologique, Paris, France.
Insights
Thrombolytic therapy improves survival in acute myocardial infarction but faces challenges like insufficient lysis and bleeding. Research focuses on earlier treatment, better drug combinations, and improved monitoring to enhance outcomes.
Area of Science:
- Cardiology
- Thrombosis
- Emergency Medicine
Background:
- Thrombolytic therapy is a key treatment for acute myocardial infarction (MI), significantly reducing hospital mortality by 30-40%.
- Current challenges include insufficient thrombolysis in 25% of patients, reocclusion rates of 6-16%, and a 0.5% risk of intracranial hemorrhage.
- Potential improvements involve earlier medical intervention, more effective thrombolytic and antithrombotic agents, and safer drug combinations with enhanced laboratory monitoring.
Purpose of the Study:
- To review the current status and challenges of thrombolytic therapy in acute myocardial infarction (MI).
- To explore potential improvements in thrombolytic therapy for MI.
- To discuss the evolving role of thrombolysis in acute pulmonary embolism (PE) and acute ischemic stroke.
Main Methods:
- Review of existing literature and megatrials on thrombolytic therapy.
- Analysis of efficacy, safety concerns, and proposed improvements for thrombolysis in MI.
- Evaluation of current evidence for thrombolysis in PE and stroke.
Main Results:
- Thrombolysis significantly reduces mortality in acute MI but is limited by efficacy and safety concerns.
- Improved outcomes in MI may be achieved through earlier treatment, combination therapies, and better monitoring.
- Thrombolysis for PE shows potential but lacks mortality reduction data; its use in stroke is still experimental.
Conclusions:
- Optimizing thrombolytic therapy for acute MI requires addressing lysis failure, reocclusion, and bleeding risks.
- Further research is needed to establish the mortality benefits of thrombolysis in PE.
- Thrombolysis for acute ischemic stroke holds promise but requires extensive clinical trials to define its benefit-risk ratio.
Abstract:
A considerable amount of work has been devoted to thrombolytic therapy (about 3000 references from 1991 to 1995 in a Medline search). The most important and well established indication of thrombolytic treatment is acute myocardial infarction (MI). Megatrials have evidenced a significant 30 to 40% reduction in hospital mortality in the treated patients. However, lack of sufficient thrombolysis in approximately 25% of patients, reocclusion in 6 to 16% of patients and intracranial hemorrhage in about 0.5% of patients are the main concerns regarding thrombolysis. Three approaches should improve the results of thrombolytic therapy in acute MI: earlier medical treatment, use of more efficacious thrombolytic agents in combination with more active antithrombotic agents and reduction of severe bleeding with safer combination of drugs. An improved of laboratory monitoring may also reduce the incidence of severe hemorrhagic events. In acute pulmonary embolism (PE), a change of indication for treatment based on echocardiography and high probability ventilation-perfusion lung scan results (without requiring pulmonary angiography) could broaden the use of thrombolysis. However, thus far, there has not been a demonstration of a reduction in mortality in large controlled studies. Thrombolysis in acute ischemic stroke is an attractive treatment but thrombolytic treatment is still at an experimental stage. However, the successful use of rt-PA in acute MI has renewed the interest in thrombolysis for focal cerebro-vascular ischaemia. Large controlled studies with SK, rt-PA or UK locally or intravenously administered have been recently undertaken to evaluate the benefit/risk ratio of treatment which seems surprisingly variable in different subgroups of patients.(ABSTRACT TRUNCATED AT 250 WORDS)